Animace načítání

Stránka se připravuje...

Přihlásit se Registrovat se
29 046 právních předpisů

Další údaje zde

Technická podpora

Poskytujeme technickou podporu zdarma

Zavolejte nám

+420 777 717 492

Plné znění - 32020R1182

  1. Úvodní strana
  2. Právní předpisy EU
  3. Plné znění - 32020R1182

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

Chci získat výhodný přístup

XXXXXXXX XXXXXX X XXXXXXXXX XXXXXXXXX (XX) 2020/1182

xx xxx 19. xxxxxx 2020,

kterým xx xxx xxxxx xxxxxxxxxxxx xxxxxxxxxxx a xxxxxxxxx xxxxxxx mění xxxx 3 xxxxxxx XX xxxxxxxx Evropského xxxxxxxxxx x Xxxx (XX) x. 1272/2008 x xxxxxxxxxxx, xxxxxxxxxx x xxxxxx látek x xxxxx

(Xxxx s xxxxxxxx xxx EHP)

EVROPSKÁ XXXXXX,

x xxxxxxx xx Xxxxxxx x xxxxxxxxx Xxxxxxxx xxxx,

x xxxxxxx xx xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Rady (XX) x. 1272/2008 xx xxx 16. xxxxxxxx 2008 o klasifikaci, xxxxxxxxxx x balení xxxxx a směsí, x xxxxx x xxxxxxx xxxxxxx 67/548/XXX x 1999/45/XX a x změně xxxxxxxx (XX) x. 1907/2006&xxxx;(1), x xxxxxxx xx xx. 37 xxxx. 5 xxxxxxxxx xxxxxxxx,

xxxxxxxx x xxxxx xxxxxxx:

(1)

Xxxxxxx 3 v xxxxx 3 přílohy XX xxxxxxxx (XX) x. 1272/2008 obsahuje xxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx nebezpečných xxxxx xx základě kritérií xxxxxxxxxxx x xxxxxxx 2 až 5 xxxxxxx X xxxxxxxxx xxxxxxxx.

(2)

Xxxxxxxx xxxxxxxx xxx xxxxxxxx látky („xxxxxxxx“) xxxx v souladu x xxxxxxx 37 xxxxxxxx (XX) č. 1272/2008 xxxxxxxxxx xxxxxx xx zavedení xxxxxxxxxxxxx xxxxxxxxxxx a označení xxxxxxxxx látek x xxxxxxxxxxx xxxx zrušení xxxxxxxxxxxxxxx xxxxxxxxxxx a xxxxxxxx xxxxxxxxx jiných xxxxx. Xx xxxxxxx xxxxxxxxxx&xxxx;(2) k xxxxx xxxxxxx, xxxxx xxxxx Xxxxx xxx posuzování xxxxx („XXX“) agentury, xxxxx x xxxxxxxxxx xxxxxxxxxxxx xxxxx, xx xxxxxx xxxxxx, xxxxxxxxxxxx xx xxxxxx harmonizované xxxxxxxxxxx x označení xxxxxxxxx látek. Xxxxxxx xxxxxxxxxx xxxxxx RAC xxxx:

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx kyseliny xxxxxxx... %[X ≤ 70 %],

—

xxxxxxxxxx ze xxx 9. xxxxxx 2018 xxxxxxx xxxxxx z xxxxxxx křemíku (x xxxxxxx < 3 μx,xxxxx &xx; 5 μx x xxxxxx xxxxx ≥ 3:1),

—

stanovisko xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxx(xxxxx)xxxxxx,

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx tris(2-methoxyethoxy)vinylsilanu, 6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 xxxxxxx xxxxxxxx-xxxxxxxxx,

—

xxxxxxxxxx ze xxx 8. června 2018 ohledně xxxxxxxxxxx xxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxx (X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)-xxxx, xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxxx, [Cu-HDO],

—

stanovisko xx xxx 14. září 2018 xxxxxxx xxxxxxxxxx-xxxxxxxxx, [1] stannanu, dioktyl-, xxx(xxxx acyloxy) derivátů [2],

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxx[xxx,x]xxxxxxxx, xxxxxxx[x,x]xxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 ohledně xxxxxxxxxx (XXX), (1XX,2XX,5XX;1XX,2XX,5XX)-2-(4-xxxxxxxxxxx)-5-xxxxxxxxx-1-(1X-1,2,4-xxxxxxx-1-xxxxxxxx)xxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxx(2-(2-xxxxxxxxxxxxx)xxxxx)xxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx ze xxx 8. června 2018 xxxxxxx xxxxxxxxxxxxxx (XXX), (2RS,3RS)-1-(4-chlorofenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-olu,

—

stanovisko xx xxx 8. xxxxxx 2018 ohledně 2,2-bis(brommethyl)propan-1,3-diolu,

—

stanovisko xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxx, (2E)-3,7-dimethylokta-2,6-dien-1-olu,

—

stanovisko xx xxx 28. xxxxx 2019 ohledně 2-(4-xxxx-xxxxxxxxxxx)xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx XXXX-xxxxxxxxxx (XXX), S-ethyl (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxxx, X-xxxxx 4-chlor-o-tolyloxythioacetátu,

—

stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx,

—

xxxxxxxxxx ze dne 14. září 2018 xxxxxxx 4-{[(6-xxxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xxx, xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxx-xxxxxxx (XXX), methyl 4- [(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx X-(+)-xxxxxx xxxxxxxx, (2X)-2-xxxxxxxxxxxxxxxx kyseliny,

—

stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx 2-xxxxxxxxxxxx-xxxxxxxx,

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 xxxxxxx xxxxxxxxxx xxxxxxxx …%,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx, [xxxxxxxxxxx xxxxxxxx z natria-N-(hydroxymethyl)glycinátu],

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx (xxxxx-XXX-xxxxx)xxxxxxxxxxx xxxxxxxxxx, cyklohexyl(hydroxy)diazen-1-oxidu, xxxxxxxx soli, [X-XXX],

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxxx-xxxxxxxxxxx, X-xxxxx-X,X-xxxxxxxxxxxxxxxxx-1-xxxxxxx-xxxxx-xxxxxxx, xxxxxxxxxxx-xxxxx-xxxxxxx [XXX],

—

xxxxxxxxxx ze dne 9. xxxxxx 2018 xxxxxxx (2XX)-2-[4-(4-xxxxxxxxxxx)-2(xxxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xxx, mefentriflukonazolu,

—

stanovisko xx dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxx (ISO), 1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxxx,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxx-xxxxx, (X-4)-xxx[1-(xxxxxxx-xxxxx-X)xxxxxxx-2(1X)-xxxxxxx-xxxxx-X]xxxxx,

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx 3-xxxxx-4-(xxxxxxxxxxx)-1-[3-xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xxx, xxxxxxxxxxxxxxx (ISO),

—

stanovisko xx xxx 30. listopadu 2018 xxxxxxx 4,5-dichlor-2-oktyl-2H-isothiazol-3-onu, [XXXXX],

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 xxxxxxx 2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xxx, [XXXX],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxxx, xxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 ohledně X-(xxxxxxxxxxxxx)xxxxxxxxxx, xxxxxxxxxxxxxxxxxx, [NMA],

—

stanovisko xx xxx 15. xxxxx 2018 xxxxxxx 5-fluor-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)fenyl]-1H-pyrazol-4-karboxamidu, 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx iprovalikarbu (XXX), xxxxxxxxx [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxxx,

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxx (XXX), X-xxxxx-4,5-xxxxxxxx-2(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 ohledně xxxxxxx, výtažku [xxxx xxxxxxxx xx xxxxxxx xx xxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx bez xxxxxxxx, xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxx xxxxxxxxx],

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 ohledně xxxxxxxx xxxxxxx …%[X&xx; 70 %],

—

xxxxxxxxxx x 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxx, [X4],

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx pirimifos-methylu (XXX), X-[2-(xxxxxxxxxxx)-6-xxxxxxxxxxxxxxx-4-xx]-X,X-xxxxxxxx-xxxxxxxxxxxxx,

—

xxxxxxxxxx xx 30. listopadu 2018 xxxxxxx xxxxxxx,

—

xxxxxxxxxx ze xxx 14. září 2018 ohledně xxxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně 2-xxxxxxxxxx-10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxx-xxxxxxxxx, [XXXX],

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 ohledně 2-xxxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxxx,

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 ohledně x-xxx(2,3-xxxxxxxxxxxx)xxxxxxx, xxxxxxxxxx-xxxxxxxxxx-xxxxxx,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx tribenuron-methylu (XXX), xxxxxx 2-[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)-X-xxxxxxxxxxxxxxxxxxxxxxxx]xxxxxxxx,

—

xxxxxxxxxx ze xxx 8. června 2018 xxxxxxx xxxxxxxxxxxxx (XXX), xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 ohledně xxxxxxxxxxxx (ISO), (RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl-methansulfonátu,

—

stanovisko xx dne 30. xxxxxxxxx 2018 xxxxxxx 2,4-xxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 14. září 2018 xxxxxxx xxxxxxxxxx (ISO), 2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxx (ISO), 2-xxxxx-2X-xxxxxxxxxx-3-xxx, [XXX],

—

xxxxxxxxxx xx xxx 14. xxxx 2018 ohledně xxxxxxxxxx (XXX), 3-xxxxxxx-5-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně xxxxxxxxxxxx (XXX), trans-5-(4-chlorfenyl)-N-cyklohexyl-4-methyl-2-oxo-3-thiazolidin-karboxamidu,

—

stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx pymetrozinu (XXX), (X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxx-xxxxx)-1,2,4-xxxxxxx-3(2X)-xxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 ohledně xxxxxxxxxxxx (XXX), xxxxxxx xxxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxxx, [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthematu,

—

stanovisko xx xxx 14. září 2018 xxxxxxx-xxxxx, ethylmethylketoximu, xxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx bis(α,α-dimethylbenzyl)-peroxidu,

—

stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx rozvětveného xxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze dne 30. xxxxxxxxx 2018 xxxxxxx xxxxx 2-(1-(xxxxxxxxxxxxxxxxxxxxxxxx) xxxxxxxxx)xxxxxxxx, xxxxx 2-[4-(diethylamin)-2-hydroxybenzoyl]benzoátu.

(3)

Pokud xxx x xxxxx xxxxx (číslo XXX 7439–92–1 x indexová xxxxx 082–013–00–1 (olovo x xxxxxx; [xxxxxx xxxxxx &xx; 1 xx];) x 082–014–00–7 (xxxxxxxx olovo; [xxxxxx xxxxxx ≥ 1 xx];)), XXX xx xxxx stanovisku ze xxx 30. xxxxxxxxx 2018 xxxxxx xxxxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx xx celistvou x xxxxxxxxx xxxxx. Xxxxx xxxxxxxx x nižší xxxxxxxxx xxxxxxxxxxx celistvé xxxxx, xxxxxx xxxxxxxxx xxxxx, xx specifické xxxxxxx xxxxxx xxxxxx x vzhledem x xxxxx xxxxxxxxxxxxxxx klasifikaci x xxxxxxxxxx x xxxxxxxxxx forem xxxxxx xxxx v existujících xxxxxxxxx x xxxxxxx XX xxxx XXX xxxxxxx xxxxx xxxxxxxxx xxxx, zda xx xxx xx celistvou x xxxxxxxxx xxxxx xxxxx xxxxxxx xxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx. Xxxxx xxxx xxxx xxxxxxxxxx xxxx vědecké xxxxxxxx, x xxxxx xxxxxxx, xx environmentální xxxxxxxxxxx xxx celistvou xxxxx, xxx xx xxxxxxxxxx xxxxxxxxxx výboru RAC, xxxxxx xxx xxxxxx. Xxxxxxxxxxxxxxx xxxxxxxxxxx pro xxxxxxxxx formu xxxxx xxxxxx xxxxxxxx do xxxxxxx XX nařízení (XX) x. 1272/2008, xxxxx XXX nebude xxx xxxxxxx předložit xxxxxxxxxx stanovisko.

(4)

Pokud xxx x látku 2-xxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxx, (xxxxx XXX 111-76-2), pro xxxxx xxxxxxxxxxxxx „akutní xxxxxxxx (xxxxxxxxx)“ xxxx xxxxxxxxxx xxxx xxxxxxx xxxxxxxx, xx kterých xxxxxxx, xx klasifikace xxx xxxx třídu nebezpečnosti xxxxxxxxxxxx xx xxxxxxxxxx xxxxxx XXX, xxx xx xxxxxxx na xxxxxxxx xxxxxxx, nemusí xxx xxxxxx. Tato xxxxx xxxxxxxxxxxxx xx xxxxx xxxxxx xxx x příloze XX xxxxxxxx (ES) x. 1272/2008 xxxxxxx, dokud XXX xxxxxx xxx xxxxxxx předložit x xxxxx xxxxx informacím xxxxxxxxxx xxxxxxxxxx; všechny xxxxxxx xxxxx xxxxxxxxxxxxx, x xxxxxxx xxxxxxxxx xxxxxxxxxx výboru XXX, xx xxxxxxxx xxx xxxx.

(5)

Xxxxxxxx (ES) x. 1272/2008 xx xxxxx xxxx být xxxxxxxxxxxxx xxxxxxxx xxxxxxx.

(6)

Xxxxxxxxxx xxxxxx xxxx aktualizovaných xxxxxxxxxxxxxxx xxxxxxxxxxx xx xxxxxx xxx, x xxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx požadavků, xxxxxxxxxx xxxxx, xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx xxxx xx xx, xxx přizpůsobili xxxxxxxxxx x xxxxxx xxxxx x xxxxx xxxxx xxxx xxxxxxxxxxx xxxxxxxxxxxx x xxxxxxx xxxxxxxxx xxxxxx. Tato xxxx xx xxxxxx nezbytná x xxxx, xxx xxxxxxxxxx měli xxxxxxxx xxxx xxxxxxxx xxxxxxxx xxxxx x xxxxxxxxx xxxxxxxx xxxxxxxxxx dalších xxxxxxxx požadavků, xxxxx xxxxxxxx v xxxxxxxx xxxx xxxxxxxxxxx xxxxx xxxxxx xxxxxxxx. Tyto xxxxxxxxx mohou zahrnovat xxxxxxxxx xxxxxxxxx x xx. 22 xxxx. 1 písm. x) xxxxxxxx Evropského parlamentu x Xxxx (XX) x. 1907/2006&xxxx;(3) nebo xxxxxxxxx xxxxxxxxx v xxxxxx 50 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (EU) x. 528/2012&xxxx;(4).

(7)

Xxxxxxxxxxx by xxxx xxxx xxx xxxxxxxx, xxx xxxxx xxxx xxxxxxxxxx xxxxxxxx se xxxxxxxxxxx, označování x xxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx dnem použitelnosti xxxxxx xxxxxxxx. Xx xx x souladu x xxxxxxxxx xxxxx xx. 61 xxxx. 2 nařízení (XX) x. 1272/2008,

XXXXXXX XXXX XXXXXXXX:

Xxxxxx 1

Změny nařízení (XX) č. 1272/2008

Tabulka 3 x xxxxx 3 přílohy XX xxxxxxxx (XX) x. 1272/2008 xx xxxx x xxxxxxx s xxxxxxxx xxxxxx xxxxxxxx.

Xxxxxx 2

Xxxxx x xxxxxxxx a xxxxxxxxxxxx

Xxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx xxxx xx vyhlášení x Xxxxxxx xxxxxxxx Xxxxxxxx xxxx.

Xxxxxxx xx xxx xxx 1. března 2022.

Xxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx článku xxxxx xxx xxxxx x xxxxx xxxxxxxxxxxxx, xxxxxxxxxx x xxxxxx x souladu s xxxxxxxxx (ES) č. 1272/2008 ve znění xxxxxx nařízení ještě xxxxx xxxx 1. xxxxxx 2022.

Toto xxxxxxxx je xxxxxxx v xxxxx xxxxxxx x přímo xxxxxxxxxx xx všech xxxxxxxxx xxxxxxx.

X Xxxxxxx xxx 19. xxxxxx 2020.

Xx Xxxxxx

Xxxxxx VON XXX XXXXX

xxxxxxxxxxx

(1)&xxxx;&xxxx;xxxxXx. xxxx. X 353, 31.12.2008, x. 1.

(2)&xxxx;&xxxx;Xxxxxxxxxx xxxx xxxxxxxx xx xxxx xxxxxxxxxxx xxxxxxx: xxxxx://xxxx.xxxxxx.xx/xxxxxxxx-xx-xxx-xxxxxxxxxx-xxxxx-xxxxxxx/-/xxxxxxx/xxxx/-/xxXxxxxx/-/xxxXxxxxx/-/xxx_xxxxxxxXxxx/-/xxx_xxxxxxxXx/-/xxx_xxxxxx_xxxxxx/Xxxxxxx+Xxxxxxx/xxx_xxxxxxxxxXxxx/-/xxx_xxxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxxxxxxXxxx/-/xxx_xxxxxxxx_xxxxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxxxxXxxx/-/xxx_xxxxxxxx_xxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxx/-/xxx_xxxxxxxxx/-/xxx_xxxxxxxxxxXxxx/-/xxx_xxxxxxxxxxXx/-/xxx_xxxxxxxxxx_xxxxxxxxx/-/

(3)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 1907/2006 ze xxx 18. xxxxxxxx 2006

o xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx x omezování xxxxxxxxxx xxxxx, o xxxxxxx Xxxxxxxx xxxxxxxx pro xxxxxxxx xxxxx, o xxxxx směrnice 1999/45/ES x x xxxxxxx xxxxxxxx Xxxx (XXX) x. 793/93, xxxxxxxx Xxxxxx (ES) x. 1488/94, xxxxxxxx Rady 76/769/XXX x směrnic Xxxxxx 91/155/EHS, 93/67/XXX, 93/105/XX a 2000/21/XX (Xx. xxxx. L 396, 30.12.2006, s. 1).

(4)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx (EU) x. 528/2012 ze xxx 22. xxxxxx 2012

x xxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxx x jejich xxxxxxxxx

(Xx. xxxx. X 167, 27.6.2012, s. 1).

XXXXXXX

X xxxxxxx VI xxxxxxxx (XX) x. 1272/2008 xx xxxxxxx 3 x části 3 xxxx takto:

1)

Vkládají xx tyto položky:

Indexové xxxxx

Xxxxxxxx název

Číslo ES

Číslo XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx koncent. limity, xxxxxxxxxxxxx xxxxxxx x XXX

Xxxxxxxx

Xxxx xxxx x xxxxxxxxx nebezpečnosti

Kódy xxxxxxxxxxxx xxx x nebezpečnosti

Kódy xxxxxxxxxxx xxxxxxx x xxxxxxxxxx xxxx

Xxxx standardních xxx x xxxxxxxxxxxxx

Xxxx xxxxx. xxxxxxxxxxxx vět x xxxxxxxxxxxxx

„007-030-00-3

xxxxxxxx dusičná …% [X ≤ 70 %]

231-714-2

7697-37-2.

Xx. Liq. 3

Xxxxx Xxx. 3

Xxxx Xxxx. 1 X

X272

X331

X314

XXX03

XXX06

XXX05

Xxx

X272

X331

X314

XXX071

Xx. Xxx. 3; X272: X ≥ 65 %

xxxxxxxxx: ATE = 2,65 mg/l (xxxx)

Xxxx Xxxx. 1 X; X314: X ≥ 20 %

Xxxx Corr. 1X; H314: 5 % ≤ X &xx; 20 %

B“

„014-048-00-5

vlákna x karbidu xxxxxxx (x xxxxxxx < 3 μx, xxxxx &xx; 5 μx x s poměrem xxxxx ≥ 3:1)

206-991-8

409-21-2

308076-74-6

Carc. 1X

X350x

XXX08

Xxx

X350x“

„014-049-00-0

xxxxxxxxxxxxxxxxxxxx; xxxxxxxxxx(xxxxx)xxxxx

220-449-8

2768-02-7

Xxxx Xxxx. 1X

X317

XXX07

Xxx

X317“

„014-050-00-6

xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxx;

6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxx

213-934-0

1067-53-4

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„016-098-00-3

xxxxxxxx-xxxxxxxx

210-871-0

624-92-0

Xxxx. Xxx. 2

Xxxxx Xxx. 3

Xxxxx Xxx. 3

STOT XX 3

XXXX XX 1

Xxx Xxxxx. 2

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X225

X331

X301

X336

X370 (horní xxxxxxx xxxxx, xxxxxxxxx)

X319

X317

X400

X410

XXX02

XXX06

XXX08

XXX09

Xxx

X225

X331

X301

X336

X370 (xxxxx xxxxxxx xxxxx, xxxxxxxxx)

X319

X317

X410

xxxxxxxxx: XXX = 5 xx/x (xxxx)

xxxxxx: XXX = 190 xx/xx XX

X = 1

X = 10“

„029-024-00-X

xxxxxxxxxxx xxx;

[xxxxx částic: xx 0,9 xx a xx 6,0 xx; xxxxx částic: od 0,494 xx 0,949 xx]

231-159-6

7440-50-8

Xxxxxxx Xxxxxxx 2

X411

XXX09

X411“

„029-025-00-5

xxx(X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)xxx;

xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxx;

[Xx-XXX]

239-703-4

312600-89-8

15627-09-5

Xxxx. Xxx. 1

Xxxxx Xxx. 4

XXXX XX 2

Eye Xxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X228

X302

X373 (xxxxx)

X318

X400

X410

XXX02

XXX07

XXX08

XXX05

XXX09

Xxx

X228

X302

X373 (xxxxx)

X318

X410

xxxxxx: XXX = 360 xx/xx XX

X = 1

X = 1“

„050-031-00-9

dioktylcín-dilaurát; [1]

xxxxxxx, xxxxxxx-, xxx(xxxx xxxxxxx) xxxxxxxx [2]

222-883-3 [1] 293-901-5 [2]

3648-18-8 [1] 91648-39-4 [2]

Xxxx. 1X

XXXX XX 1

H360D

H372 (imunitní xxxxxx)

XXX08

Xxx

X360X

X372 (xxxxxxxx systém)“

„601-092-00-0

dibenzo[def,p]chrysen;

dibenzo[a,l]pyren

205-886-4

191-30-0

Carc. 1X

Xxxx. 2

X350

X341

XXX08

Xxx

X350

X341

Xxxx. 1B; X350: X ≥ 0,001 %“

„603-237-00-3

ipkonazol (XXX);

(1XX,2XX,5XX;1XX,2XX,5XX)-2-(4-xxxxxxxxxxx)-5-xxxxxxxxx-1-(1X-1,2,4-xxxxxxx-1-xxxxxxxx)xxxxxxxxxxxxx

–

125225-28-7

115850-69-6

115937-89-8

Xxxx. 1X

Xxxxx Xxx. 4

XXXX XX 2

Aquatic Xxxxxxx 1

X360X

X302

X373 (xxx, xxxx, xxxxx)

X410

XXX08

XXX07

XXX09

Xxx

X360X

X302

X373 (oči, xxxx, xxxxx)

X410

xxxxxx: XXX = 500 xx/xx XX

X = 100“

„603-238-00-9

xxx(2-(2-xxxxxxxxxxxxx)xxxxx)-xxxxx; xxxxxxxxx

205-594-7

143-24-8

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„603-239-00-4

xxxxxxxxxxxxx (ISO);

(2RS,3RS)-1-(4-chlorfenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol

–

76738-62-0

Repr. 2

Acute Xxx. 4

Xxxxx Xxx. 4

Xxx Xxxxx. 2

Xxxxxxx Xxxxx 1

Aquatic Chronic 1

X361x

X332

X302

X319

X400

X410

XXX08

XXX07

XXX09

Xxx

X361x

X332

X302

X319

X410

xxxxxxxxx: XXX = 3,13 xx/x (xxxxx xxxx xxxx)

xxxxxx: ATE = 490 xx/xx XX

X = 10

M = 10“

„603-240-00-X

2,2-xxx(xxxxxxxxxx)xxxxxx-1,3-xxxx

221-967-7

3296-90-0

Xxxx. 1X

Xxxx. 1X

X350

X340

XXX08

Xxx

X350

X340“

„603-241-00-5

xxxxxxxx;

(2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xx

203-377-1

106-24-1

Xxxx Xxxx. 1

X317

XXX07

Xxx

X317“

„605-041-00-3

2-(4-xxxx-xxxxxxxxxxx)xxxxxxxx

201-289-8

80-54-6

Xxxx. 1X

X360Xx

XXX08

Xxx

X360Xx“

„607-738-00-8

XXXX-xxxxxxxxx (XXX);

X-xxxxx (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxx; X-xxxxx 4-chlor-o-tolyloxythioacetát

246-831-4

25319-90-8

Acute Tox. 4

XXXX XX. 2

Aquatic Xxxxx 1 Xxxxxxx Xxxxxxx 1

X302

X373 (xxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxx)

X410

xxxxxx: XXX = 450 xx/xx XX

X = 10

X = 10“

„607-740-00-9

xxxxxxxxxx-xxxxxx

248-523-5

27554-26-3

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„607-741-00-4

4-{[(6-xxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xx; flupyradifuron

–

951659-40-8

Acute Xxx. 4

XXXX RE 2

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X302

X373 (xxxxxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxxxxxx)

X410

xxxxxx: ATE = 500 xx/xx XX

X = 10

M = 10“

„607-742-00-X

xxxxxxxxxxxxx-xxxxxx (XXX);

xxxxxx-4-[(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxx

–

317815-83-1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1000

X = 1000“

„607-743-00-5

X-(+)-xxxxxx xxxxxxxx;

(2 S)-2-hydroxypropanová xxxxxxxx

201-196-2

79-33-4

Xxxx Xxxx. 1C

Eye Xxx. 1

X314

X318

XXX05

Xxx

X314

XXX071“

„607-744-00-0

2-xxxxxxxxxxxxxxxxxxx

221-499-3

3121-61-7

Xxxx. Xxx. 3

Xxxx. 2

Xxxx. 1B

Acute Xxx. 3

Xxxxx Tox. 4

Xxxx Xxxx. 1X

Xxx Xxx. 1

Xxxx Sens. 1

X226

X341

X360XX

X331

X302

X314

X318

X317

XXX02

XXX05

XXX06

XXX08

Xxx

X226

X341

X360XX

X331

X302

X314

X317

XXX071

xxxxxxxxx: ATE = 2,7 xx/x (xxxx)

xxxxxx: XXX = 404 xx/xx TH“

„607-745-00-6

glyoxylová xxxxxxxx …%

206-058-5

298-12-4

Xxx Xxx. 1

Xxxx Xxxx. 1X

X318

X317

XXX05

XXX07

Xxx

X318

X317

X“

„607-746-00-1

xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxx;

[xxxxxxxxxxx uvolněný x natrium-N-(hydroxymethyl)glycinátu]

274-357-8

70161-44-3

Carc. 1X

Xxxx. 2

Xxxxx Tox. 4

Acute Xxx. 4

STOT XX 3

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

Xxxx Xxxx. 1

X350

X341

X332

X302

X335

X315

X319

X317

XXX08

XXX07

Xxx

X350

X341

X332

X302

X335

X315

X319

X317

xxxxxxxxx: ATE = 3 mg/l (xxxxx xxxx mlha)

orální: XXX = 1&xxxx;100 mg/kg XX

8

9“

„611-181-00-6

(xxxxx-XXX-xxxxx)xxxxxxxxxx draselný;

cyklohexylhydroxydiazen-1-oxid, draselná xxx;

[X-XXX]

–

66603-10-9

Xxxx. Sol. 1

Acute Xxx. 3

XXXX RE 2

Xxxx Irrit. 2

Xxx Xxx. 1

Xxxxxxx Xxxxxxx 2

X228

X301

X373 (xxxxx)

X315

X318

X411

XXX02

XXX06

XXX08

XXX05

XXX09

Xxx

X228

X301

X373 (játra)

H315

H318

H411

orální: XXX = 136 xx/xx TH“

„612-294-00-3

mecetroniumetilsulfát;

N-ethyl-N,N-dimethylhexadekan-1-aminium-ethyl-sulfát;

mecetronium-ethyl-sulfát;

[MES]

221-106-5

3006-10-8

Skin Corr. 1

Xxx Xxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X314

X318

X400

X410

XXX05

XXX09

Xxx

X314

X410

XXX071

X = 100

M = 1&xxxx;000 “

„613-331-00-6

(2XX)-2-[4-(4-xxxxxxxxxxx)-2-(xxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xx;

xxxxxxxxxxxxxxxxxx

–

1417782-03-6

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H317

H400

H410

GHS07

GHS09

Wng

H317

H410

M = 1

M = 1“

„613-332-00-1

xxxxxxxxxxxxxxx (ISO);

1-(4-{4-[5-(2,6-difluorfenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluormethyl)-1H-pyrazol-1-yl]ethanon

–

1003318-67-9

Aquatic Chronic 1

X410

XXX09

Xxx

X410

X = 1“

„613-333-00-7

xxxxxxxxx-xxxxx; (X-4)-xxx[1-(xxxxxxx-.xxxxx.X)xxxxxxx-2(1X)-xxxxxxxx-.xxxxx.X]xxxxx

236-671-3

13463-41-7

Xxxx. 1X

Xxxxx Xxx. 2

Xxxxx Xxx. 3

XXXX XX 1

Eye Xxx. 1

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X360X

X330

X301

X372

X318

X400

X410

XXX08

XXX06

XXX05

XXX09

Xxx

X360X

X330

X301

X372

X318

X410

xxxxxxxxx: XXX = 0,14 xx/x (xxxxx nebo xxxx)

xxxxxx: XXX = 221 xx/xx XX

X = 1&xxxx;000

X = 10“

„613-334-00-2

xxxxxxxxxxxxxx (XXX);

3-xxxxx-4-(xxxxxxxxxxx)-1-[3-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xx

262-661-3

61213-25-0

Xxxx. 1X

Xxxxx Xxx. 4

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Aquatic Chronic 1

X360XX

X302

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X360XX

X302

X317

X410

xxxxxx: XXX = 500 xx/xx XX

X = 100

X = 100“

„613-335-00-8

4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xx; [XXXXX]

264-843-8

64359-81-5

Xxxxx Xxx. 2

Xxxxx Tox. 4

Xxxx Xxxx. 1

Xxx Dam. 1

Xxxx Xxxx. 1 X

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

H330

H302

H314

H318

H317

H400

H410

GHS06

GHS05

GHS09

Dgr

H330

H302

H314

H317

H410

EUH071

inhalační: ATE = 0,16 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 567 xx/xx TH

Skin Xxxxx. 2; H315: 0,025 % ≤ X &xx; 5 %

Eye Xxxxx. 2; H319: 0,025 % ≤ X < 3 %

Xxxx Sens. 1 X; X317: X ≥ 0,0015 %

X = 100

X = 100“

„613-336-00-3

2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx;

[XXXX]

–

2527-66-4

Xxxxx Xxx. 4

Xxxxx Xxx. 3

Xxxx Xxxx. 1X

Xxx Dam. 1

Xxxx Xxxx. 1 A

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 2

X312

X301

X314

X318

X317

X400

X411

XXX06

XXX05

XXX09

Xxx

X312

X301

X314

X317

X410

XXX071

xxxxxxxx: ATE = 1&xxxx;100 xx/xx TH

orální: XXX = 175 xx/xx TH

Skin Xxxx. 1 A; H317: X ≥ 0,0015 %

X = 1“

„616-228-00-4

3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’-xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxx;

xxxxxxxxxxxx

–

907204-31-3

Xxxx.

Xxxxxxx Xxxxx 1

Aquatic Chronic 1

X362

X400

X410

XXX09

Xxx

X362

X410

X = 1

X = 1“

„616-230-00-5

X-(xxxxxxxxxxxxx)xxxxxxxxx; xxxxxxxxxxxxxxxxx; [XXX]

213-103-2

924-42-5

Xxxx. 1X

Xxxx. 1B

STOT XX 1

X350

X340

X372 (xxxxxxxxx xxxxxxx xxxxxx)

XXX08

Xxx

X350

X340

X372 (periferní xxxxxxx xxxxxx)“

„616-231-00-0

5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxx; 2’-[(RS)-1,3-dimethylbutyl]-5-fluor-1,3-dimethylpyrazol-4-karboxanilid;

penflufen

–

494793-67-8

Carc. 2

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

X351

X400

X410

XXX08

XXX09

Xxx

X351

X410

X = 1

X = 1“

„616-232-00-6

iprovalikarb (XXX);

xxxxxxxxx [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxx

–

140923-17-7

Xxxx. 2

X351

XXX08

Xxx

X351“

„616-233-00-1

xxxxxxxxxx (XXX);

X-xxxxx-4,5-xxxxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxx

–

175217-20-6

XXXX XX 2

Xxxxxxx Xxxxxxx 2

X373

X411

XXX08

XXX09

Xxx

X373

X411“

„650-057-00-6

Xxxxxxx, xxxxxxx [xxxx xxxxxxxx xx xxxxxxx ze semen xxxxxxxx Xxxxxxxxxxx xxxxxx xxx skořápek, xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxx xxxxxxxxx]

283-644-7

84696-25-3

Xxxxxxx Xxxxxxx 3

H412

H412“

2)

položky odpovídající xxxxxxxxx číslům 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616–014–00–0 a 617–006–00-X xx xxxxxxxxx xxxxxx xxxxxxxxx:

Xxxxxxxx číslo

Chemický xxxxx

Xxxxx XX

Xxxxx CAS

Klasifikace

Označení

Specifické xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx a ATE

Poznámky

Kódy xxxx a xxxxxxxxx xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx vět x xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx xxxxxxx a xxxxxxxxxx xxxx

Xxxx xxxxxxxxxxxx xxx x nebezpečnosti

Kódy xxxxx. xxxxxxxxxxxx vět x xxxxxxxxxxxxx

„007-004-00-1

xxxxxxxx xxxxxxx …% [X > 70 %]

231-714-2

7697-37-2

Xx. Liq. 2

Acute Xxx. 1

Xxxx Corr. 1 A

H272

H330

H314

GHS03

GHS06

GHS05

Dgr

H272

H330

H314

EUH071

Ox. Xxx. 2; X272: X ≥ 99 %

Xx. Xxx. 3; H272: 70 % ≤ X &xx; 99 %

X“

„014-018-00-1

xxxxxxxxxxxxxxxxxxxxxxxxxxx;

[X4]

209-136-7

556-67-2

Xxxx. 2

Aquatic Chronic 1

X361x ***

X410

XXX08

XXX09

Xxx

X361x ***

X410

X = 10“

„015-134-00-5

xxxxxxxxx-xxxxxx (XXX);

X-[2-(xxxxxxxxxxx)-6-xxxxxxxxxxxxxxx-4-xx]-X,X-xxxxxxxx-xxxxxxxxxxxxx

249-528-5

29232-93-7

Xxxxx Xxx. 4

STOT XX 1

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X302

X372 (xxxxxxx xxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X372 (xxxxxxx xxxxxx)

X410

xxxxxx: XXX = 1&xxxx;414 xx/xx XX

X = 1&xxxx;000

X = 1&xxxx;000 “

„015-181-00-1

xxxxxx

232-260-8

7803-51-2

Xxxx. Gas 1

Xxxxx. Xxx

Xxxxx Xxx. 1

Skin Xxxx. 1X

Xxxxxxx Acute 1

X220

X330

X314

X400

XXX02

XXX04

XXX06

XXX05

XXX09

Xxx

X220

X330

X314

X400

xxxxxxxxx:

XXX = 10 xxxX (plyny)

U“

„050-021-00-4

dichlordioktylstannan

222-583-2

3542-36-7

Repr. 1X

Xxxxx Xxx. 2

STOT RE 1

Xxxxxxx Xxxxxxx 3

X360X

X330

X372 **

X412

XXX08

XXX06

Xxx

X360X

X330

X372 **

X412

Xxxx. 1X; X360 D: X ≥ 0,03 %

xxxxxxxxx: XXX = 0.098 xx/X (prach xxxx xxxx)“

„050-027-00-7

2-xxxxxxxxxx 10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxxxxxxxxxx; [XXXX]

239-622-4

15571-58-1

Xxxx. 1X

XXXX RE 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360X

X372 (xxxxxxxx xxxxxx)

X400

X410

XXX08

XXX09

Xxx

X360X

X372 (xxxxxxxx xxxxxx)

X410“

„082-013-00-1

xxxxxxx xxxxxx; [xxxxxx částic < 1 xx]

231-100-4

7439-92-1

Xxxx. 1 X

Xxxx.

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H360FD

H362

H400

H410

GHS08

GHS09

Dgr

H360FD X362

X410

Xxxx. 1 A; X360X: X ≥ 0,03 %

X = 1

X = 10“

„603-014-00-0

2-xxxxxxxxxxx-1-xx;

xxxxxxxxxxxxxxxxxxxxxxxxxxxx

203-905-0

111-76-2

Xxxxx Xxx. 4*

Xxxxx Xxx. 4

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

X332

X302

X315

X319

XXX07

Xxx

X332

X302

X315

X319

xxxxxx: XXX = 1&xxxx;200 xx/xx TH“

„603-065-00-9

m-bis(2,3-epoxypropoxy)benzen;

resorcinoldiglycidylether

202-987-5

101-90-6

Carc. 1X

Xxxx. 2

Acute Xxx. 3

Xxxxx Xxx. 4

Xxxx Xxxxx. 2

Eye Xxxxx. 2

Xxxx Xxxx. 1

Aquatic Xxxxxxx 3

X350

X341

X311

X302

X315

X319

X317

X412

XXX08

XXX06

Xxx

X350

X341

X311

X302

X315

X319

X317

X412

xxxxxxxx: XXX = 300 mg/kg XX xxxxxx: ATE = 500 xx/xx XX“

„607-177-00-9

xxxxxxxxxx-xxxxxx (ISO);

methyl-2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylkarbamoylsulfamoyl]benzoát

401-190-1

101200-48-0

STOT XX 2

Xxxx Xxxx. 1

Aquatic Xxxxx 1

Xxxxxxx Chronic 1

X373

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X373

X317

X410

X = 100

M = 100“

„607-256-00-8

xxxxxxxxxxxx (XXX);

xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxx

–

131860-33-8

Xxxxx Tox. 3

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X331

X400

X410

XXX06

XXX09

Xxx

X331

X410

xxxxxxxxx:

XXX = 0,7 xx/x (xxxxx xxxx xxxx)

X = 10

X = 10“

„607-314-00-2

xxxxxxxxxxx (XXX);

(XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx xxxxxxxxxxxxxx

247-525-3

26225-79-6

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1

X = 1“

„609-041-00-4

2,4-xxxxxxxxxxxx

200-087-7

51-28-5

Xxxxx Xxx. 3 *

Acute Xxx. 3

Xxxxx Tox. 2

XXXX XX 1

Aquatic Xxxxx 1

X331

X311

X300

X372

X400

XXX06

XXX08

XXX09

Xxx

X331

X311

X300

X372

X400

xxxxxxxx: ATE = 300 xx/xx XX xxxxxx: XXX = 30 xx/xx XX“

„609-064-00-X

xxxxxxxxx (ISO);

2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyklohexandion

–

104206-82-8

Repr. 2

XXXX XX 2

Aquatic Xxxxx 1

Xxxxxxx Chronic 1

X361x

X373 (xxx, xxxxxxx xxxxxx)

X400

X410

XXX08

XXX09

Xxx

X361x

X373 (xxx, xxxxxxx xxxxxx)

X410

X = 10

X = 10“

„613-112-00-5

xxxxxxxxxx (XXX);

2-xxxxx-2X-xxxxxxxxxx-3-xx; [XXX]

247-761-7

26530-20-1

Xxxxx Xxx. 2

Xxxxx Tox. 3

Xxxxx Tox. 3

Xxxx Xxxx. 1

Eye Xxx. 1

Xxxx Xxxx. 1 X

Xxxxxxx Xxxxx 1 Xxxxxxx Chronic 1

X330

X311

X301

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X311

X301

X314

X317

X410

XXX071

xxxxxxxxx: XXX = 0,27 xx/x (xxxxx xxxx xxxx)

xxxxxxxx: XXX = 311 xx/xx XX xxxxxx: ATE = 125 mg/kg XX

Xxxx Xxxx. 1 X; X317: X ≥ 0,0015 %

X = 100

X = 100“

„613-115-00-1

xxxxxxxxx (XXX);

3-xxxxxxx-5-xxxxxxxxxxxxxx

233-000-6

10004-44-1

Xxxx. 2

Xxxxx Tox. 4

Xxx Xxx. 1

Xxxx Xxxx. 1

Xxxxxxx Chronic 2

X361x

X302

X318

X317

X411

XXX08

XXX07

XXX05

XXX09

Xxx

X361x

X302

X318

X317

X411

xxxxxx: XXX = 1&xxxx;600 mg/kg XX“

„613-125-00-6

xxxxxxxxxxx (XXX);

xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxx

–

78587-05-0

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1

X = 1“

„613-202-00-4

xxxxxxxxxx (XXX);

(X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxxxxxxxx)-1,2,4-xxxxxxx-3(2X)-xx

–

123312-89-0

Xxxx. 2

Xxxx. 2

Xxxxxxx Xxxxxxx 1

H351

H361fd

H410

GHS08

GHS09

Wng

H351

H361fd

H410

M = 1“

„613-259-00-5

xxxxxxxxxxx (XXX);

xxxxxxx xxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxx; [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxxxx-xxxxxxxxxxxxx

428-790-6

72963-72-5

Xxxx. 2

Xxxxx Xxx. 4

Acute Xxx. 4

XXXX SE 2

Aquatic Xxxxx 1

Xxxxxxx Chronic 1

X351

X332

X302

X371 (xxxxxxx xxxxxx; xxxxxx, inhalační)

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H332

H302

H371 (nervový xxxxxx; xxxxxx, xxxxxxxxx)

X410

xxxxxxxxx: XXX = 1,4 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 550 mg/kg TH

M = 10

M = 10“

„616-014-00-0

xxxxx-xx-xxxx; xxxxxxxxxxxxxxxxxx, ethyl(methyl)ketonoxim

202-496-6

96-29-7

Carc. 1X

Xxxxx Xxx. 4

Acute Xxx. 3

XXXX XX 3

XXXX XX 1

XXXX XX 2

Xxxx Xxxxx. 2

Xxx Dam. 1

Xxxx Xxxx. 1

X350

X312

X301

X336

X370 (xxxxx xxxxxxx cesty)

H373 (xxxxxx xxxx)

X315

X318

X317

XXX08

XXX06

XXX05

Xxx

X350

X312

X301

X336

X370 (xxxxx xxxxxxx xxxxx)

X373 (xxxxxx xxxx)

X315

X318

X317

xxxxxxxx: XXX = 1&xxxx;100 xx/xx TH orální: XXX = 100 xx/xx TH“

„617-006-00-X

bis(α,α-dimethylbenzyl)peroxid

201-279-3

80-43-3

Org. Xxxxx. X

Xxxx. 1X

Xxxx Xxxxx. 2

Xxx Irrit. 2

Xxxxxxx Xxxxxxx 2

X242

X360X

X315

X319

X411

XXX02

XXX08

XXX07

XXX09

Xxx

X242

X360X

X315

X319

X411“

3)

xxxxxxx odpovídající xxxxxxxxx xxxxxx 601-064-00-8 x 607-693-00-4 xx xxxxxxx.